Humax TF ADC

Drug Profile

Humax TF ADC

Alternative Names: HuMax-TF; HuMax-TF-ADC; TF-011-MMAE; Tisotumab vedotin

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Genmab
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 16 Jun 2017 Adverse events data from a phase I/II trial in solid tumours released by Genmab
  • 08 Jun 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Hungary (Parenteral) (EudraCT2016-004743-37)
  • 31 Mar 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top